Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in... Letters Conflict of Interest Disclosures: Dr Matsuo reported receiving an honorarium an increased risk of capsule rupture, which was associated with from Chugai, textbook editorial expense from Springer, and investigator increased mortality. An increased rate of capsular rupture meeting attendance expense from VBL Therapeutics outside the submitted among women with benign adnexal cysts undergoing MIS has work. Dr Matsuzaki reported receiving research grants from MSD outside the been previously reported, but this association has received little submitted work. Dr Klar reported receiving consultation fees from Tesaro and GSK outside the submitted work. Dr Roman reported receiving consultation attention for women with ovarian cancer. fees from Quantgene outside the submitted work. Dr Sood reported receiving Previous work on the prognostic significance of capsular consultation fees from Merck and Kiyatec, being a shareholder for Bio-Path rupture has reported mixed findings. Theoretically, rupture Holdings, and receiving research grants from M-Trap outside the submitted of the ovarian capsule may result in tumor seeding of the ab- work. Dr Wright reported receiving grants from Merck and consultation fees from Clovis Oncology outside the submitted work. No other disclosures dominal cavity and may be associated with increased were reported. mortality. We recognize a number of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

JAMA Oncology , Volume 6 (7) – Jul 30, 2020

Loading next page...
 
/lp/american-medical-association/immunotherapy-with-programmed-cell-death-1-vs-programmed-cell-death-jgMjTleLlv
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.0631
Publisher site
See Article on Publisher Site

Abstract

Letters Conflict of Interest Disclosures: Dr Matsuo reported receiving an honorarium an increased risk of capsule rupture, which was associated with from Chugai, textbook editorial expense from Springer, and investigator increased mortality. An increased rate of capsular rupture meeting attendance expense from VBL Therapeutics outside the submitted among women with benign adnexal cysts undergoing MIS has work. Dr Matsuzaki reported receiving research grants from MSD outside the been previously reported, but this association has received little submitted work. Dr Klar reported receiving consultation fees from Tesaro and GSK outside the submitted work. Dr Roman reported receiving consultation attention for women with ovarian cancer. fees from Quantgene outside the submitted work. Dr Sood reported receiving Previous work on the prognostic significance of capsular consultation fees from Merck and Kiyatec, being a shareholder for Bio-Path rupture has reported mixed findings. Theoretically, rupture Holdings, and receiving research grants from M-Trap outside the submitted of the ovarian capsule may result in tumor seeding of the ab- work. Dr Wright reported receiving grants from Merck and consultation fees from Clovis Oncology outside the submitted work. No other disclosures dominal cavity and may be associated with increased were reported. mortality. We recognize a number of

Journal

JAMA OncologyAmerican Medical Association

Published: Jul 30, 2020

References